Genomics Platform

We are looking forward to the partnership with the BIH

The administrative agreement is signed, the Berlin Institute of Health (BIH) will become the third pillar of the Charité. "We are excited about the privileged partnership," says Professor Thomas Sommer, interim Scientific Director of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC).

Group picture: (left to right): Steffen Krach (State Secretary for Education and Research), Prof. Thomas Sommer (interim Scientific Director, MDC), Andrea Runow (interim Administrative Director, BIH ), Michael Müller (Governing Mayor of Berlin), Anja Karliczek (Federal Minister for Education and Research), Prof. Axel Radlach Pries (interim Chairman, BIH), Prof. Karl Max Einhäupl (Chairman, Charité), Georg Schütte (State Secretary at the BMBF).

"The MDC has outstanding specialists in vascular medicine and single-cell analysis and is a driver for innovation. As a privileged partner, the MDC will play a decisive role in helping the BIH fulfill its mission of accelerating the translation of research findings from the lab to the clinic. That is good for patients in Germany and good for our research, so we are very pleased," said Thomas Sommer, interim Scientific Director of the MDC. The pursuit of translational, patient-oriented research and the application of our discoveries to improve human health are very close to our heart,” emphasizes Sommer.

Forschung in der Genomik-Plattform, einer gemeinsamen Infrastruktur von MDC und BIH

‟It is especially positive that we can bring the vascular medicine expertise we have here in Berlin to bear in the BIH in an optimal way. The MDC is home to outstanding specialists who are studying diseases of the blood vessels, such as heart failure, heart attack, and stroke, and are already successfully collaborating with physicians at Charité, for example, on the BeLOVE study. Now we can expand this collaboration,” says Sommer. The study aims to follow 10,000 patients who suffer from acute diseases of the blood vessels over many years in order to find out why some people survive the disease relatively well and why others don’t. 

Cooperation is already a reality

As a result of the already proven and excellent cooperation between our researchers and clinicians at the Charité, we will make rapid progress in the interest of patients.
Thomas Sommer
Thomas Sommer Wissenschaftlicher Vorstand (komm.) des MDC

The MDC has also attained internationally recognized excellence in single-cell analysis, a cutting-edge research approach that ultimately seeks to reliably predict disease onset and progression and to develop better treatment options. “In this field, the MDC already has strong ties to Charité, for example, when it comes to data sharing and analysis.” Here Sommer pointed out the joint research efforts in pediatric oncology. “We look forward to the intensive collaboration, whose aim is personalized medicine. We will be able to expedite scientific progress that benefits patients through the already excellent and fruitful collaboration of our researchers with Charité’s clinicians,” Sommer added.

Sommer stresses that the MDC is a driver of innovation and has state-of-the-art technologies and facilities, some of which have been jointly developed ‒ and are extensively used – by the MDC, Charité, and the BIH. This cooperation must continue, he says, highlighting the close proximity of the MDC to Germany’s largest university hospital.

Further information

Press contact 

Jutta Kramm 
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)  
Head of the Communications Department  
+49 (0)30-9406-2140 
jutta.kramm@mdc-berlin.de 

 

The Max Delbrück Center for Molecular Medicine (MDC)

 

The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) was founded in Berlin in 1992. It is named for the German-American physicist Max Delbrück, who was awarded the 1969 Nobel Prize in Physiology and Medicine. The MDC's mission is to study molecular mechanisms in order to understand the origins of disease and thus be able to diagnose, prevent and fight it better and more effectively. In these efforts the MDC cooperates with the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) as well as with national partners such as the German Center for Cardiovascular Research and numerous international research institutions. More than 1,600 staff and guests from nearly 60 countries work at the MDC, just under 1,300 of them in scientific research. The MDC is funded by the German Federal Ministry of Education and Research (90 percent) and the State of Berlin (10 percent), and is a member of the Helmholtz Association of German Research Centers. www.mdc-berlin.de